Ryne Bio
Rajesh Mistry currently serves as Chief Financial Officer at Kenai Therapeutics, a position held since October 2022. Previously, Rajesh was Chief Financial Officer at TriSalus Life Sciences from May 2020 to October 2022. Prior to that role, Rajesh worked at Option Care Health as Head of Corporate Development (M&A) from June 2018 to November 2019. Rajesh also held the position of Director of Strategic Finance & Investor Relations at Melinta Therapeutics from June 2014 to June 2018, and served as Senior Manager of Corporate Development & Strategy (M&A) at Baxter Healthcare from February 2008 to June 2014. Rajesh began a career in finance as an Investment Banking Analyst at A.G. Edwards Capital Markets from June 2007 to January 2008. Rajesh earned a Bachelor of Science (B.S.) in Finance from Indiana University - Kelley School of Business.
This person is not in any teams
This person is not in any offices
Ryne Bio
Ryne Bio is a biotechnology company advancing off-the-shelf neuron replacement therapies as potent disease-modifying treatments for neurological disorders. To achieve this they leverage induced pluripotent stem cell (iPSC) technology, which enables precision manufacture of therapeutically relevant human neurons. Their lead program targeting Parkinson’s Disease is a cryopreserved iPSC dopamine neuron progenitor (RNDP-001) that can be reliably manufactured and delivered